Oklahoma legislation · 2026 Regular Session
Oklahoma SB1344: Prescription drugs; creating the Insulin Access and Affordability Program; requiring certain financial support and agreement. Effective date. Emergency.
Status: Signed into law, May 5, 2026
What the bill says
An Act relating to prescription drugs; creating the Insulin Access and Affordability Program for specified purposes; directing the State Department of Health to provide certain financial support; requiring certain agreement with nonprofit pharmaceutical manufacturer; describing agreement; requiring certain annual reporting; providing for codification; providing an effective date; and declaring an emergency. SUBJECT: Patient access to affordable insulin.
From the enrolled text, April 29, 2026:
An Act relating to prescription drugs; creating the Insulin Access and Affordability Program for specified purposes; directing the State Department of Health to provide certain financial support; requiring certain agreement with nonprofit pharmaceutical manufacturer; describing agreement; requiring certain annual reporting; providing for codification; providing an effective date; and declaring an emergency. SUBJECT: Patient access to affordable insulin SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1-271 of Title 63, unless there is created a duplication in numbering, reads as follows: A. There is hereby created the Insulin Access and Affordability Program, which shall be administered by the State Department of Health for the purpose of increasing patient access to affordable insulin in this state, reducing prescription drug costs for consumers and payors, bolstering American manufacturing of pharmaceuticals, increasing marketplace competition, and addressing shortages in the market for generic insulin. B. The Department shall, with funds appropriated by the Legislature, provide financial support to one or more pharmaceutical manufacturers that manufacture, or are currently developing, a fast- acting biosimilar insulin. Each such pharmaceutical manufacturer shall manufacture the fast-acting biosimilar insulin in the United States. C. Prior to disbursement of any funds, the Department shall enter into a memorandum of understanding (MOU) with the pharmaceutical manufacturer or manufacturers, and each manufacturer shall …